Pharmacogenomics in solid tumors: Integrating germline and somatic genetic variability for precision oncology
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: Solid tumors exhibit substantial interindividual variability in therapeutic response and drug-related toxicity, which cannot be fully explained by clinical or tumor-specific factors alone. Pharmacogenomics has emerged as a critical component of precision oncology by elucidating how both germline and somatic genetic variability influence anticancer drug efficacy and safety. Objective: This review provides a comprehensive and clinically oriented overview of pharmacogenomics in solid tumour’s, highlighting actionable gene–drug associations, translational relevance, implementation challenges, and emerging innovations shaping future oncology practice. Methods: A narrative review of peer-reviewed literature published between 2020 and 2026 was conducted using PubMed, EMBASE, Web of Science, and Google Scholar. Human studies, systematic reviews, meta-analyses, and clinical guidelines focusing on pharmacogenomic biomarkers and gene–drug interactions in solid tumors were included. Results: Germline variants in key drug-metabolizing enzymes, including CYP2D6, DPYD, and UGT1A1, significantly influence drug exposure, toxicity risk, and treatment outcomes across multiple solid tumors. Somatic alterations such as EGFR, KRAS, and BRCA1/2 mutations guide targeted therapy selection, resistance prediction, and tumor-agnostic treatment strategies. Despite robust evidence supporting pharmacogenomic-guided therapy, clinical implementation remains inconsistent due to infrastructural limitations, cost concerns, and gaps in clinician education. Conclusion: Pharmacogenomics represents a foundational pillar of precision oncology by integrating host and tumor genetic information to optimize therapeutic decision-making. Advances in polygenic modeling, liquid biopsy technologies, artificial intelligence, and multi-omics integration are expected to accelerate clinical adoption. Systematic implementation of pharmacogenomics has the potential to improve treatment efficacy, reduce toxicity, and enhance patient outcomes in solid tumors.
Fields of Study & Subjects
Pharmacogenetics and Drug Metabolism
Cancer Genomics and Diagnostics
BRCA gene mutations in cancer
Publication details
- Journal / source
- GSC Biological and Pharmaceutical Sciences
- Volume
- 34
- Issue
- 3
- Pages
- 247–254
- Publication date
- 30 March 2026
- Language
- EN